【摘要】 目的探讨上皮性卵巢癌患者化疗前及化疗后血清中纤溶酶原激活剂(u PA)含量的变化与预后的相关性。方法 107例卵巢恶性肿瘤患者行手术初治后,采用酶联免疫吸附试验(ELISA)检测化疗前及化疗后血清中u PA的含量。102例相同年龄段的正常健康妇女作为对照。结果卵巢癌患者化疗前及化疗后血清中u PA的含量均明显高于正常对照组,差异有统计学意义(P<0.05)。卵巢癌患者化疗前血清中u PA的水平高于化疗后,两者的差异有统计学意义(P<0.05)。单因素生存分析中,化疗前u PA水平、化疗后u PA水平、FIGO分期、残余瘤灶直径大小和有无淋巴结转移是影响卵巢癌患者无进展生存期(progression-free survival,PFS)和总生存期(overall survival,OS)的相关因素(P<0.05)。Cox比例风险模型分析显示,化疗前u PA水平和有无淋巴结转移与预后明显相关(P<0.05)。结论卵巢癌患者化疗前后血清中u PA水平高于正常人群,且其水平高低与FIGO分期、淋巴结转移及残存瘤灶大小高度相关。化疗前血清中u PA含量可作为评价患者PFS和OS的独立预后因子。更多还原

【Abstract】 Objective To investigate variation and prognostic value of serum urokinase-type plasminigen activator( u PA) before and after chemotherapy in patients with epithelial ovarian carcinoma. Methods One hundred and seven patients with ovarian carcinoma receive chemotherapy after cytoreductive surgery. Serum u PA levels were measured by enzyme-linked immunosorbent assay( ELISA) before chemotherapy and after 6 cycles of chemotherapy. One hundred and two health subjects served as controls. Results Serum u PA levels of patients were significantly higher than that of healthy women before and after chemotherapy( both P < 0. 05); while u PA levels in patients before chemotherapy was significantly higher than those after the chemotherapy. Kaplan-M eier analysis indicated the serum u PA level before and after chemotherapy,FIGO stage,residual tumor size and lymph node metastasis were all associated with progression-free survival( PFS) and overall survival( OS) of ovarian carcinoma patients. Multivariate Cox regression analysis revealed that the serum u PA level and lymph node metastasis were independent prognostic factors for both PFS and OS( all P <0. 05). Conclusion Patients with epithelial ovarian carcinoma have high serum u PA levels both before and after chemotherapy. Pre-chemotherapy u PA level might be used for prognosis of ovarian carcinoma patients.更多还原